Genetic Technologies Limited · ASX:GTG
Genetic Technologies — Investor Presentation (May 2023)
23 slides from Genetic Technologies's investor presentation, May 2, 2023
Slide 1: Genetic Technologies - Investor Webinar
Genetic Technologies - Investor Webinar The Future: Unlocking personalised preventative medicine 2 May, 2023 Authorised by the Board of Directors of Genetic Technologies Limited ASX: GTG NASDAQ: GENE
Slide 2: World leading portfolio
World leading portfolio Most comprehensive guideline driven portfolio for human and animal health. + Patented GeneType Multi Risk Test + Non-Invasive Prenatal Testing (NIPT) * Carrier screen testing + Pharmacogenomics * Oncogenetic diseases + Pet care Revenues anchored by our 3 brands to seize a mul
Slide 3: Comprehensive genomics-based testing via a multi-brand strategy
Comprehensive genomics-based testings via a multi-brand strategy Medical & Payer Business to Business (B2B) a “4 Oncology - GTG Cardiovascular Prenatal NIPT Carrier testing Clinical & Molecular Metabolic Consumer initiated testing (CIT) with medical supervision La oe — 4 genetype Vv Expanded Carrier
Slide 4: Global Overview
Global Overview Employees Countries
Slide 5: Snapshot and Achievements last months
Snapshot and Achievements last 12 months GeneType commercialization ¥ 9 Tests NOW commercially available in the US the geneType Multi-Risk test y >100 medical practices on-boarded launching the foundation of geneType Hubs in Australia v Presentations by Dr Erika Spaeth at: yv ASCOGI Cancers Symposiu
Slide 6: Delivering Revenue and Growth - Q3 FY23
Delivering Revenue and Growth - Q3 FY23 Cash Receipts (A$'000) Q3 CASH RECEIPTS CASH BALANCE A$2.2m A$10.5m* GROSS MARGIN March GROSS MARGIN A$1.13m 49% *2ppts OS FY22 OS FY23 YTD FY22 Strategic & Operational Highlights: + March Quarter FY23 receipts A$4.22 million + Launched Melanoma, Pancreatic Ca
Slide 7: Core '4'
Core ‘4’ * [od genelype Demonstrate clinical validity & clinical utility of geneType tests EasyDNA & Affinity DNA Revenue Growth: Tests, Channels. & Markets Innovation: Next Generation of capability - Starting with Epigenetics e » => 4 geneType ane genstype — @@, easyDNA ~ 7
Slide 8: geneType: New Comprehensive Breast and Ovarian Cancer test
9 geneType NEW Comprehensive Breast and Ovarian Cancer test Evaluates a woman's risk of developing Breast and/or Ovarian Cancer in women 30 years+ Hereditor Testing of genes associated hereditary breast ond ‘evorian cancer syndrome. integrated with elinicat ond fomiliol risk foctors. World's First C
Slide 9: New diseases now available in the US
pepe NEW - 9 Diseases now available in the US GeneType can identify patients ’at risk’ before onset and aid in the early detection and treatment. GeneType Risk assessment test for breast cancer has demonstrated improved early stage detectig 18% and saving approx. US$1.4B per annum4 for the US payer
Slide 10: New Peer Review Publications Released
NEW - 3 Peer Review Publications Released Our Scientific team continues to achieve scientific publication milestones, accepted in three peer-reviewed journals during the quarter Cancer Prevention Research Validation of an abridged breast cancer risk prediction model for the general population. spoet
Slide 11: New Strategic Alliance with Qiagen
NEW Strategic Alliance with Qiagen The alliance will establish and develop a ‘Centre of Excellence’ facility in Australia QIAGEN will support the enhancement of GTG capabilities through software, hardware, consumable and technical solutions, including: + Reagents and QIAGEN’s proprietary QCIl softwa
Slide 12: geneType Priority Pathway to Market
, Ce geneType Genelype Priority Pathway to Market Medical & Payer Payer coverage is the key driver of revenues for geneType Business to Business (545) geneType Risk Assessment Tests more widely Coverage from payers in the US will accelerate adoption of R H : . Budget Impact Model (BIM) demonstrates
Slide 13: Economic Modeling in the US Payer System
Geneve Economic Modeling in the US Payer System! The economic benefit to the payers in the US is US$14B per annum $73 69% - 74% 6.8%-9.2% US Payor system overall increase in Supplemental will save per women getting screening frequency patient per year screened 14.8% - 8.8% 07% - 67% Interval Cancers
Slide 14: DTC - Growth strategy for EasyDNA
DTC - Growth strategy for EasyDNA y > PHASE 1 PHASE 2 Brand Re-Ignition Revenue and Growth Focus Brand Refresh Website Refresh Improved Lead Gen New Sales Channels Multi-brand Portfolio Website Development Google Ads Amazon store front Facebook Ads EasyDNA Brand Refresh First-party data collection T
Slide 15: EasyDNA eCommerce Growth strategy
= ° = easyDNA ~~ APA BAAD eee ea ate A+ —~C A eCommerce Growtn strat ~OS) Bs EasyDNA Search e Home Human Tests ¥ Health Tests ¥ Animal Tests ¥ About Us ¥ Resources ¥ Contact ER NO Home Human Tests v Health Tests v Animal Tests v AboutUs ¥ Resources » Contact DNA Testin: of-Mind , fo EMomee Eentioe G
Slide 16: Thank you
Thank you Investor Relations Adrian Mulcahy Market Eye - Automic Group val www.linkedin.com/company/genetype-limited M: +61 438 630 422 E: adrian. jr www.genetype.com
Slide 17: Appendices
Appendices W
Slide 18: Board and Management
Board and Management: Sales and Scientific expertise leading GTG Mr. Peter Rubinstein Dr. Lindsay Wakefield Mr Nick Burrows (us BEc, LLB MBBS B.Comm, FAICD, FCA, Chairman Non-Executive Director FGIA, FTIA, F Fin Non - Executive Director Non - Executive Director . . Dr. Jerzy “George” y Erika Spaeth
Slide 19: Strong Scientific Leadership: Advisory Board
Strong Scientific Leadership: Advisory Board © 8 Professor Jon Emery MBBCh MA DPhil FRACGP MRCGP Research & Education Lead, Primary Care Integration, Victorian Comprehensive Cancer Centre Herman Chair of Primary Care Cancer Research, University of Melbourne Professor Finlay Macrae AO MBBS, MD, FRACP
Slide 20: Financial Overview
Financial Overview + Net cash outflow of A$7.2 million for the nine months to 31 March 2023. We continue to grow EasyDNA and Affinity DNA brand sales and develop and commercialise our geneType tests + Cash reserves will be directed to: + to support the commercialisation of the GeneType Multi Risk te
Slide 21: Corporate Overview
G # genelype he ¢ “4 Corporate Overview Top 50 share registry breakdown BNY Mellon mBoard & Management = Other Dual Listed on the ASX and Nasdaq Financial Information Share price (AUD) as at 25 April 2023 0.3c ADR price (USD) as at 25 February 2023 $1.08 Other, 24% Ord Shares on Issue (M) 11,542 ASX
Slide 22: Our Intellectual Property
CO, geneType Our Intellectual Property 4 Patents granted in the US + Patent No: US 11,257,569, Methods of assessing risk of developing a severe response to Coronavirus infection + Patent No: US 11,072,830, Methods for breast cancer risk assessment + Patent No: US 10,683,549, Methods for assessing ri
Slide 23: Defined Terms
Defined Terms ‘Common Complex Diseases (CCP)- A complex disease is caused by the interaction of multiple genes and environmental factors. Complex diseases are also called multifactorial. Examples of common complex diseases include cancer and heart disease. Polygenic risk score - o number associated
Genetic Technologies — Investor Presentation (May 2023) on 6ix